Safety, Adherence and Persistence in a Real-World Cohort of German MS Patients Newly Treated With Ocrelizumab: First Insights From the CONFIDENCE Study

Safety, Adherence and Persistence in a Real-World Cohort of German MS Patients Newly Treated With Ocrelizumab: First Insights From the CONFIDENCE Study

BackgroundReal-world relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS) populations may be more diverse than in clinical trials. Here, we present a first analysis of safety, adherence and persistence data from a real-world cohort of patients newly treated with ocrelizumab.MethodsCO...

Full description

Bibliographic Details
Main Authors: Martin S. Weber, Mathias Buttmann, Sven G. Meuth, Petra Dirks, Erwan Muros-Le Rouzic, Julius C. Eggebrecht, Stefanie Hieke-Schulz, Jost Leemhuis, Tjalf Ziemssen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Neurology
Subjects:
neurodegenerative diseases
multiple sclerosis
non-interventional study (NIS)
real-world cohort
safety
drug (or treatment) persistence
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2022.863105/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2022.863105/full

Similar Items